Vaccination of patients at risk between 65 and 79 years old is conditioned by the arrival of more vaccines from Pfizer. In the European Union, Portugal is the fifth country with the highest percentage of doses of vaccines against covid-19 administered in relation to the total of those distributed.
People aged 65 to 79 with pathologies associated with a higher risk of serious illness and mortality from covid-19 are the group that received the fewest vaccines. This situation is due to the current vaccination strategy in Portugal and due to the consequent lack of vaccines from Pfizer, advances the Public.
Bearing in mind that doses of the Pfizer-BioNtech vaccine are being channeled to the elderly over 80 years of age, and since the AstraZeneca vaccine is not recommended for people over 65, this priority group will have to wait until arrival of a large volume of doses of the Pfizer vaccine, which should not occur until April.
However, the Order of Doctors defended, on Wednesday, the administration of the vaccine of AstraZeneca over 65 years old, claiming that there is data “sufficiently robust” for this to happen.
Yesterday, the German vaccines committee approved the administration of the AstraZeneca vaccine to people over 65 years old, changing the previous decision, similarly to what France, Belgium and Sweden have already done.
This scenario is still under study in Portugal.
On the other hand, the percentage of elderly people over 80 years of age with at least one dose of the vaccine is already over 34%. The DGS data, released this Tuesday, point to more than 282 thousand doses administered in this age group. This is the age group that has risen the most: two weeks ago, only 12% had received the vaccine.
Portugal acquired about 22 million doses of various vaccines against covid-19. The purchase is part of an agreement between the European Union and six pharmaceutical companies. For now, there are three vaccines approved by the European Medicines Agency and that are being administered in Portugal: BioNTech / Pfizer, Moderna and AstraZeneca.
The vaccines of Janssen (decision scheduled for March), CureVac and Sanofi / GSK are awaiting approval.
The European Union has also concluded exploratory negotiations with two more laboratories: Novavax (in phase 3 clinical trial) and Valneva, says the Express.
The second dose of the covid-19 vaccine should take place three weeks after the first dose.
Ana Isabel Moura //